Genitourinary Partnering Terms and Agreements

Introduction

Abstract

Description

The Genitourinary Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the genitourinary partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter genitourinary partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors genitourinary technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1,000 links to online copies of actual genitourinary deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of genitourinary dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in genitourinary dealmaking since 2007 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading genitourinary deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of genitourinary deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all genitourinary deals since 2007 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all genitourinary partnering deals signed and announced since 2007. The chapter is organized by specific genitourinary therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all genitourinary partnering deals signed and announced since 2007. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in genitourinary partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of genitourinary technologies and products.

Benefits

Genitourinary Partnering Terms and Agreements provides the reader with the following key benefits:

• In-depth understanding of genitourinary deal trends since 2007
• Access genitourinary deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between genitourinary partner companies
• Comprehensive access to over 1,000 links to actual genitourinary deals entered into by the world's biopharma companies
• Indepth review of genitourinary deals entered into by the leading fifty bigpharma companies
• Benchmark the key deal terms companies have agreed in previous deals
• Identify key terms under which companies partner genitourinary opportunities
• Uncover companies actively partnering genitourinary opportunities

Table of Contents

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in genitourinary dealmaking

• 2.1. Introduction
• 2.2. Genitourinary partnering over the years
• 2.3. Bigpharma genitourinary dealmaking activity
• 2.4. Bigpharma not active in genitourinary
• 2.5. Genitourinary partnering by deal type
• 2.6. Genitourinary partnering by industry sector
• 2.7. Genitourinary partnering by stage of development
• 2.8. Genitourinary partnering by technology type
• 2.9. Genitourinary partnering by genitourinary indication
• 2.10. Average deal terms for genitourinary
  • 2.10.1 Genitourinary headline values
  • 2.10.2 Genitourinary upfront payments
  • 2.10.3 Genitourinary milestone payments
  • 2.10.4 Genitourinary royalty rates

Chapter 3 - Leading genitourinary deals

• 3.1. Introduction
• 3.2. Top genitourinary deals by value
• 3.3. Top genitourinary deals involving bigpharma

Chapter 4 - Bigpharma genitourinary deals

• 4.1. Introduction
• 4.2. How to use bigpharma partnering deals
• 4.3. Bigpharma genitourinary partnering company profiles
  • Abbott
  • Actavis
  • Allergan
  • Amgen
  • Aspen Pharmacare
  • Astellas
  • Baxter International
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Dainippon Sumitomo
  • Eisai
  • Eli Lilly
  • Gilead Sciences
  • GlaxoSmithKline
  • Grifols
  • Hospira
  • Menarini
  • Merck & Co
  • Mitsubishi Tanabe
  • Novo Nordisk
  • Pfizer
  • Roche
  • Sanofi
  • Shionogi
  • Shire
  • Takeda
  • Teva
  • Valeant
  • Warner Chilcott
  • Watson

Chapter 5 - Genitourinary partnering contracts directory

• 5.1. Introduction
• 5.2. By deal type
  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Contract service
  • Co-promotion
  • Development
  • Distribution
  • Equity purchase
  • Licensing
  • Litigation
  • Loan
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Settlement
  • Sub-license
  • Supply
  • Termination
• 5.3. By stage of development
  • Discovery
  • Formulation
  • Marketed
  • Phase I
  • Phase II
  • Phase III
  • Preclinical
  • Regulatory
• 5.4. By technology type
  • Assays
  • Biological compounds
  • Blood products
  • Devices
  • Diagnostics
  • Discovery tools
  • Drug delivery
  • Equipment
  • Facilities
  • Gene therapy
  • Genomics
  • Imaging
  • Implant
  • Nanotechnology
  • Peptides
  • Proteomics
  • Research services
  • Research supplies
  • RNA therapeutics
  • Screening
  • Small molecules

Chapter 6 - Genitourinary dealmaking by indication

• 6.1. Introduction
• 6.2. Deals by therapeutic indication
  • Genitourinary
  • Acute kidney injury
  • Amyloidosis
  • Chronic kidney disease (CKD)
  • Cystitis
  • Diabetic nephropathy
  • Dialysis
  • Frequency
  • Incontinence
  • Nocturia
  • Urgency
  • Hemolytic-uremic syndrome (HUS)
  • Kidney stones
  • Overactive bladder
  • Peyronie's disease
  • Polycystic kidney disease
  • Prostate diseases
  • Prostate enlargement
  • Prostatitis
  • Renal failure
  • Nephritis
  • Urinary tract infection (UTI)

Chapter 7 - Partnering resource center

• 7.1. Online partnering
• 7.2. Partnering events
• 7.3. Further reading on dealmaking

Appendices

• Appendix 1 - Directory of genitourinary deals by company A-Z 2007-2012
• Appendix 2 - Directory of genitourinary deals by deal type 2007-2012
• Appendix 3 - Directory of genitourinary deals by stage of development 2007-2012
• Appendix 4 - Directory of genitourinary deals by technology type 2007-2012
• Appendix 5 - Deal type definitions

• About Wildwood Ventures
• Current Partnering
• Current Agreements
• Recent titles from CurrentPartnering
• Order Form - Reports
• Order Form - Therapy Reports

Table of figures

• Figure 1: Genitourinary partnering since 2007
• Figure 2: Bigpharma - top 50 - genitourinary deals 2007 to 2012
• Figure 3: Bigpharma genitourinary deal frequency - 2007 to 2012
• Figure 4: Inactive bigpharma in genitourinary 2007-2012
• Figure 5: Genitourinary partnering by deal type since 2007
• Figure 6: Genitourinary partnering by industry sector since 2007
• Figure 7: Genitourinary partnering by stage of development since 2007
• Figure 8: Genitourinary partnering by technology type since 2007
• Figure 9: Genitourinary partnering by genitourinary target since 2007
• Figure 10: Genitourinary deals with a headline value
• Figure 11: Genitourinary deal headline value distribution, US$million - discovery stage
• Figure 12: Genitourinary deal headline value distribution, US$million - preclinical stage
• Figure 13: Genitourinary deal headline value distribution, US$million - phase I stage
• Figure 14: Genitourinary deal headline value distribution, US$million - phase II stage
• Figure 15: Genitourinary deal headline value distribution, US$million - phase III stage
• Figure 16: Genitourinary deal headline value distribution, US$million - regulatory stage
• Figure 17: Genitourinary deal headline value distribution, US$million - marketed stage
• Figure 18: Summary median headline value by stage of development, 2007-2012
• Figure 19 Genitourinary deals with upfront payment values
• Figure 20: Genitourinary deal upfront payment distribution, US$million - discovery stage
• Figure 21: Genitourinary deal upfront payment distribution, US$million - preclinical stage
• Figure 22: Genitourinary deal upfront payment distribution, US$million - phase I stage
• Figure 23: Genitourinary deal upfront payment distribution, US$million - phase II stage
• Figure 24: Genitourinary deal upfront payment distribution, US$million - phase III stage
• Figure 25: Genitourinary deal upfront payment distribution, US$million - regulatory stage
• Figure 26: Genitourinary deal upfront payment distribution, US$million - marketed stage
• Figure 27: Summary median upfront payments by stage of development, 2007-2012
• Figure 28: Genitourinary deals with milestone payments
• Figure 29: Genitourinary deal milestone distribution, US$million - discovery stage
• Figure 30: Genitourinary deal milestone distribution, US$million - preclinical stage
• Figure 31: Genitourinary deal milestone distribution, US$million - phase I stage
• Figure 32: Genitourinary deal milestone distribution, US$million - phase II stage
• Figure 33: Genitourinary deal milestone distribution, US$million - phase III stage
• Figure 34: Genitourinary deal milestone distribution, US$million - regulatory stage
• Figure 35: Genitourinary deal milestone distribution, US$million - marketed stage
• Figure 36: Genitourinary deals with royalty rates, %
• Figure 37: Genitourinary deal royalty rate distribution, US$million - discovery stage
• Figure 38: Genitourinary deal royalty rate distribution, US$million - preclinical stage
• Figure 39: Genitourinary deal royalty rate distribution, US$million - phase I stage
• Figure 40: Genitourinary deal royalty rate distribution, US$million - phase II stage
• Figure 41: Genitourinary deal royalty rate distribution, US$million - phase III stage
• Figure 42: Genitourinary deal royalty rate distribution, US$million - regulatory stage
• Figure 44: Summary median royalty rate by stage of development, 2007-2012
• Figure 45: Top genitourinary deals by value since 2007
• Figure 46: Top genitourinary deals signed by bigpharma value since 2007
• Figure 47: Online partnering resources
• Figure 48: Forthcoming partnering events

Genitourinary Partnering Terms and Agreements published by Current Partnering, a division of Wildwood Ventures Limited. This report consists of 511 Pages and the price starts from US $ 2695.

The contents of this page may be different from the latest version. Please contact us for details.